Mathematical Model To Quantify the Effects of Risk Factors on Carbapenem-Resistant Acinetobacter baumannii
暂无分享,去创建一个
M. Nikolaou | V. Tam | D. Lye | T. Ng | M. Tan
[1] T. Einarson,et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[2] A. Andremont,et al. Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design , 2013, European Journal of Clinical Microbiology & Infectious Diseases.
[3] Florian Hölzl,et al. Time Series Analysis as a Tool To Predict the Impact of Antimicrobial Restriction in Antibiotic Stewardship Programs Using the Example of Multidrug-Resistant Pseudomonas aeruginosa , 2013, Antimicrobial Agents and Chemotherapy.
[4] B. Gu,et al. Correlation Between Carbapenem Consumption and Antimicrobial Resistance Rates of Acinetobacter baumannii in a University‐Affiliated Hospital in China , 2013, Journal of clinical pharmacology.
[5] V. Tam,et al. Correlation of Hospital Carbapenem Consumption and Resistance Trends in Selected Gram-Negative Bacteria , 2012, The Annals of pharmacotherapy.
[6] M. Su,et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.
[7] Ronald N. Jones,et al. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). , 2011, The Journal of antimicrobial chemotherapy.
[8] N. Goel,et al. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. , 2011, The Journal of antimicrobial chemotherapy.
[9] K. Hızel,et al. Nosocomial imipenem-resistant Acinetobacter baumannii infections: Epidemiology and risk factors , 2010, Scandinavian journal of infectious diseases.
[10] D. Nicolau,et al. Absence of Association between Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates in 25 Hospitals , 2010, Infection Control & Hospital Epidemiology.
[11] V. Tam,et al. Surveillance and Correlation of Antibiotic Prescription and Resistance of Gram-Negative Bacteria in Singaporean Hospitals , 2010, Antimicrobial Agents and Chemotherapy.
[12] V. Peraino,et al. Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa , 2009, Antimicrobial Agents and Chemotherapy.
[13] Michael Nikolaou,et al. Pharmacodynamic Modeling of Aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: Identifying Dosing Regimens To Suppress Resistance Development , 2008, Antimicrobial Agents and Chemotherapy.
[14] Lisa L Maragakis,et al. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] L. Hsu,et al. IMP-4 and OXA β-lactamases in Acinetobacter baumannii from Singapore , 2007 .
[16] K. Ko,et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. , 2007, The Journal of antimicrobial chemotherapy.
[17] R. Polk,et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] J. Vila,et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[19] Michael Nikolaou,et al. Mathematical modelling of resistance emergence. , 2005, The Journal of antimicrobial chemotherapy.
[20] Michael Nikolaou,et al. Modelling time-kill studies to discern the pharmacodynamics of meropenem. , 2005, The Journal of antimicrobial chemotherapy.
[21] Ronald N. Jones,et al. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). , 2004, The Journal of antimicrobial chemotherapy.
[22] Tae Hyong Kim,et al. Risk Factors for Acquisition of Imipenem-Resistant Acinetobacter baumannii: a Case-Control Study , 2004, Antimicrobial Agents and Chemotherapy.
[23] K. Madaras-Kelly. Optimizing Antibiotic Use in Hospitals: The Role of Population‐Based Antibiotic Surveillance in Limiting Antibiotic Resistance Insights from the Society of Infectious Diseases Pharmacists , 2003, Pharmacotherapy.
[24] Gülseren Baran,et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[25] L. Hsu,et al. IMP-4 and OXA beta-lactamases in Acinetobacter baumannii from Singapore. , 2007, The Journal of antimicrobial chemotherapy.
[26] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .